Skip to main content
main-content

01.07.2015 | Clinical trial | Ausgabe 2/2015

Breast Cancer Research and Treatment 2/2015

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

Zeitschrift:
Breast Cancer Research and Treatment > Ausgabe 2/2015
Autoren:
Sibylle Loibl, Christian Jackisch, Bianca Lederer, Michael Untch, Stefan Paepke, Sherko Kümmel, Andreas Schneeweiss, Jens Huober, Jörn Hilfrich, Claus Hanusch, Bernd Gerber, Holger Eidtmann, Carsten Denkert, Serban Dan Costa, Jens-Uwe Blohmer, Valentina Nekljudova, Keyur Mehta, Gunter von Minckwitz
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10549-015-3479-z) contains supplementary material, which is available to authorized users.
On behalf of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) study groups.
Results were presented in parts at the 35th San Antonio Breast Cancer Symposium 2012.

Abstract

Young women with breast cancer (BC) have a worse survival partly due to more aggressive tumor characteristics; however, their response to chemotherapy seems better. We investigated to what extent the prognostic factor pathological complete remission (pCR) after neoadjuvant chemotherapy is applicable to young women. 8949 patients with primary BC and follow-up from eight German neoadjuvant trials were included. A subgroup of 1453 patients <40 years was compared with women aged 40–49 and ≥50 years regarding pCR (ypT0 ypN0), as well as disease free survival (DFS), local recurrence free survival (LRFS), distant disease free survival (DDFS), and overall survival (OS) overall, according to pCR status and subtypes defined by hormone-receptor (HR) status and HER2. pCR was strongly associated with age without a clear age cut-off. The pCR rate was significantly higher in the young compared with other age groups (20.9 vs. 17.7 vs. 13.7 %; p < 0.001). This difference was confined to triple-negative breast cancer (TNBC) and HR +/HER2−. DFS, DDFS, LRFS, and OS were significantly worse for young women. Age was independently prognostic for survival in HR +/HER2−, with women <40 years without pCR having a worse DFS compared to their counterparts with pCR. Young women are more likely to achieve pCR after neoadjuvant chemotherapy, especially in HR +/HER2− and TNBC. Age is not an important prognostic factor in TNBC and HR−/HER2 + but is in HR +/HER2−. Young women with a luminal-like BC seem to benefit more from neoadjuvant chemotherapy than older women, which needs to be taken into account.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Nur für berechtigte Nutzer zugänglich
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2015

Breast Cancer Research and Treatment 2/2015 Zur Ausgabe
  1. Sie können e.Med Gynäkologie & Urologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise